CN116407673A - Surgical liquid dressing and production process thereof - Google Patents
Surgical liquid dressing and production process thereof Download PDFInfo
- Publication number
- CN116407673A CN116407673A CN202310204044.5A CN202310204044A CN116407673A CN 116407673 A CN116407673 A CN 116407673A CN 202310204044 A CN202310204044 A CN 202310204044A CN 116407673 A CN116407673 A CN 116407673A
- Authority
- CN
- China
- Prior art keywords
- percent
- liquid dressing
- solution
- surgical liquid
- surgical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 34
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000011187 glycerol Nutrition 0.000 claims abstract description 14
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 14
- 239000000661 sodium alginate Substances 0.000 claims abstract description 14
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 14
- 239000004014 plasticizer Substances 0.000 claims abstract description 13
- 239000003906 humectant Substances 0.000 claims abstract description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- -1 acrylic ester Chemical class 0.000 claims description 13
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 11
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 2
- 206010052428 Wound Diseases 0.000 abstract description 29
- 208000027418 Wounds and injury Diseases 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 10
- 238000011084 recovery Methods 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 5
- 230000008733 trauma Effects 0.000 abstract description 5
- 206010016717 Fistula Diseases 0.000 abstract description 3
- 208000004210 Pressure Ulcer Diseases 0.000 abstract description 3
- 206010053615 Thermal burn Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000003890 fistula Effects 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to a surgical liquid dressing and a production process thereof. The material comprises the following raw materials in percentage by weight: 15.0 to 35.0 percent of rehabilitation liquid, 3.5 to 5.5 percent of antioxidant, 1.5 to 5.0 percent of polyvinylpyrrolidone, 1.0 to 2 percent of sodium alginate, 3.0 to 4.5 percent of glycerol, 0.8 to 1.4 percent of plasticizer, 3.0 to 8.0 percent of humectant and the balance of purified water. The invention contains the rehabilitation and refresh liquid, has the effects of promoting blood circulation, nourishing yin and promoting tissue regeneration, can be used for various trauma wounds such as trauma, ulcer, fistula, burn, scald, bedsore and the like, can improve the tissue repair speed of the wounded part and quickens wound recovery.
Description
Technical Field
The invention relates to a liquid dressing, in particular to a surgical liquid dressing and a production process thereof.
Background
When human skin is damaged, skin barriers are damaged, and harmful substances such as bacteria and the like easily enter the body, so that inflammation and other symptoms are caused. Band-aids and various dressings are used to protect skin wounds, disinfect and diminish inflammation, prevent infection and stop bleeding. However, such medical articles often affect the mobility of the corresponding area after the medical articles are applied to the wound surface, and are not suitable for use in some special skin areas. For this reason, liquid dressings are commercially available, which are a type of liquid medicament that is sprayed onto the wound surface of the skin and form a protective layer that acts as a physical barrier against the ingress of bacteria, the protective layer generally also having a certain permeability. The protective layer formed by the liquid dressing is very thin and is adsorbed at the wound surface without auxiliary fixation, so that the liquid dressing is suitable for wounds at various positions.
However, the current liquid dressing has the main functions of establishing a barrier, protecting a wound part from bacterial infection, and simultaneously has certain sterilization and disinfection and hemostasis effects, and the medicine components contained in the current liquid dressing have no great effect on wound recovery and skin tissue repair or have insignificant effect, so that the current liquid dressing has the main function of establishing a micro-environment relatively suitable for autonomous wound recovery. The current liquid dressing does not have a substantial promoting effect on the granulation growth at the wound.
Disclosure of Invention
The invention provides a surgical liquid dressing; solves the problem that the liquid dressing in the prior art has no substantial promotion effect on the growth of the granulation at the wound.
The technical problems of the invention are mainly solved by the following technical proposal: the surgical liquid dressing is characterized by comprising the following raw materials in percentage by weight: 15.0 to 35.0 percent of rehabilitation liquid, 3.5 to 5.5 percent of antioxidant, 1.5 to 5.0 percent of polyvinylpyrrolidone, 1.0 to 2 percent of sodium alginate, 3.0 to 4.5 percent of glycerol, 0.8 to 1.4 percent of plasticizer, 3.0 to 8.0 percent of humectant and the balance of purified water. The invention uses the characteristic that polyvinylpyrrolidone, sodium alginate, glycerol and purified water can generate macromolecular polymer with special structure, and the liquid dressing is in a colloidal complex state, thus being beneficial to the rapid formation of flexible film structure at the wound, the film has the effects of transparency, ventilation, moisture preservation and fungus blocking, being beneficial to forming a relatively sterile microenvironment suitable for wound recovery at the wound, and being capable of delaying the acting time of the dressing. The main component of the rehabilitation new liquid is the American cockroach extract, which has the effects of promoting blood circulation, nourishing yin and promoting granulation. The invention containing the rehabilitation liquid can be used for wound surfaces such as golden sore, trauma, ulcer, fistula, burn, scald, bedsore and the like, and can accelerate wound recovery.
Further, the invention also comprises 0.008-0.01% of benzalkonium bromide, and the benzalkonium bromide has the function of improving the sterilization and anti-inflammatory effects of the invention.
Further, the adhesive also comprises 0.5 to 1.2 percent of acrylic ester, wherein the acrylic ester can be one of ethyl acrylate, methyl acrylate, 2-methyl methacrylate and 2-ethyl methacrylate. The addition of the acrylic ester can improve the performance of the film formed by the liquid dressing and improve the good adhesion performance between the liquid dressing and skin tissues.
Further, the antioxidant is vitamin C or vitamin E.
Further, the plasticizer is propylene glycol, and the plasticizer has the function of accelerating the curing film-forming speed of the invention.
Furthermore, the humectant is polyethylene glycol, so that the moisturizing effect of the invention is improved.
The invention also provides a production process of the surgical liquid dressing, which comprises the surgical liquid dressing, and the production process comprises the following steps:
a. uniformly mixing polyvinylpyrrolidone, sodium alginate, plasticizer, glycerin, humectant, acrylic ester and purified water, stirring, standing for 4-8 h at normal temperature to obtain solution A;
b. adding the antioxidant into the solution A, and stirring and dissolving to obtain a solution B;
c. adding the benzalkonium bromide into the solution B, and uniformly mixing to obtain a solution C;
d. and adding the rehabilitation solution into the solution C, and uniformly mixing to obtain the surgical liquid dressing.
Therefore, compared with the prior art, the invention has the following characteristics: 1. the invention contains the rehabilitation liquid, has the effects of promoting blood circulation, nourishing yin and promoting tissue regeneration, can be used for various trauma wounds such as trauma, ulcer, fistula, burn, scald, bedsore and the like, can improve the tissue repair speed of the wounded part and quickens wound recovery;
2. the solution of the invention contains a large amount of macromolecular polymers, so that the liquid dressing is in a colloidal complex state, thus being beneficial to the liquid dressing to quickly form a flexible film structure at a wound, the film has the effects of transparency, ventilation, moisture preservation and fungus blocking, is beneficial to forming a relatively sterile microenvironment suitable for wound recovery at the wound, and can delay the acting time of the dressing.
Detailed Description
The technical scheme of the invention is further specifically described by the following examples.
In the description of the present invention, it should be understood that the terms "center," "longitudinal," "transverse," "length," "width," "thickness," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," "clockwise," "counterclockwise," etc. indicate orientations or positional relationships, which are merely for convenience in describing the present invention and simplifying the description, and do not indicate or imply that the devices or elements referred to must have a particular orientation, be configured and operated in a particular orientation, and therefore should not be construed as limiting the present invention.
Example 1: the surgical liquid dressing comprises the following raw materials in percentage by weight: 15.0 percent of rehabilitation liquid, 0.008 to 0.01 percent of benzalkonium bromide, 3.5 to 5.5 percent of vitamin E, 0.5 to 1.2 percent of acrylic ester, 1.5 to 5.0 percent of polyvinylpyrrolidone, 1.0 to 2 percent of sodium alginate, 3.0 to 4.5 percent of glycerin, 0.8 to 1.4 percent of propylene glycol, 3.0 to 8.0 percent of polyethylene glycol and the balance of purified water.
The production process of the surgical liquid dressing comprises the following steps:
a. mixing polyvinylpyrrolidone, sodium alginate, plasticizer, glycerin, humectant, acrylic ester and purified water, stirring uniformly, standing for 4h at normal temperature to obtain solution A;
b. adding the antioxidant into the solution A, and stirring and dissolving to obtain a solution B;
c. adding the benzalkonium bromide into the solution B, and uniformly mixing to obtain a solution C;
d. and adding the rehabilitation solution into the solution C, and uniformly mixing to obtain the surgical liquid dressing.
Example 2: the surgical liquid dressing comprises the following raw materials in percentage by weight: 25% of combretastatin liquid, 0.009% of benzalkonium bromide, 4.5% of vitamin E, 0.9% of acrylic ester, 3.0% of polyvinylpyrrolidone, 1.5% of sodium alginate, 4.0% of glycerin, 1.0% of propylene glycol, 5.0% of polyethylene glycol and the balance of purified water.
The production process of the surgical liquid dressing comprises the following steps:
a. mixing polyvinylpyrrolidone, sodium alginate, plasticizer, glycerin, humectant, acrylic ester and purified water, stirring uniformly, standing at normal temperature for 6h to obtain solution A;
b. adding the antioxidant into the solution A, and stirring and dissolving to obtain a solution B;
c. adding the benzalkonium bromide into the solution B, and uniformly mixing to obtain a solution C;
d. and adding the rehabilitation solution into the solution C, and uniformly mixing to obtain the surgical liquid dressing.
Example 3: the surgical liquid dressing comprises the following raw materials in percentage by weight: 35.0% of combretastatin liquid, 0.01% of benzalkonium bromide, 5.5% of vitamin E, 1.2% of acrylic ester, 5.0% of polyvinylpyrrolidone, 2% of sodium alginate, 4.5% of glycerol, 1.4% of propylene glycol, 8.0% of polyethylene glycol and the balance of purified water.
The production process of the surgical liquid dressing comprises the following steps:
a. mixing polyvinylpyrrolidone, sodium alginate, plasticizer, glycerin, humectant, acrylic ester and purified water, stirring uniformly, standing at normal temperature for 8h to obtain solution A;
b. adding the antioxidant into the solution A, and stirring and dissolving to obtain a solution B;
c. adding the benzalkonium bromide into the solution B, and uniformly mixing to obtain a solution C;
d. and adding the rehabilitation solution into the solution C, and uniformly mixing to obtain the surgical liquid dressing.
Dividing 40 experimental mice into three groups of ABCD, cutting a same back area of each mouse with a surgical knife to form a incision with the length of 10mm and the depth of about 2 mm, taking group A as a control group, wrapping and treating wounds of the mice with sterile gauze, and quantitatively spraying the liquid dressing in the example 1 once daily for three continuous days on wounds of the group B mice; group C mice were wound continuously sprayed quantitatively once daily with the liquid dressing of example 2 for three days; group D mice were wound continuously sprayed with the liquid dressing of example 3 quantitatively once daily for three days, and then the number of days required for each mouse to scab and fall was counted. The following are specific table data:
as can be seen from the table, spraying the present example on the wound site of mice can effectively accelerate the recovery rate of the wound.
Taking 20 experimental mice, equally dividing the mice into two groups EF, cutting a incision with the same back area of each mouse and the length of 10mm and the depth of about 2 mm by using a surgical knife, and quantitatively spraying the liquid dressing in the example 2 once daily for three continuous days on wounds of the mice in the group E; group F mice were wound continuously sprayed with the liquid dressing of example 2 (with vinylpyrrolidone, sodium alginate, plasticizer, glycerin, humectant, acrylate removed) daily and quantitatively once daily, and the number of days required for each mouse to scab and shed was counted. The following are specific table data:
| group of | E | F |
| Days (average value) | 9.7 | 11.3 |
The gel-like complex formed by the vinyl pyrrolidone, the sodium alginate, the plasticizer, the glycerol, the humectant and the acrylic ester can be obtained from the surface, so that the acting time of the liquid dressing can be prolonged, and the treatment effect can be improved.
It will be obvious to those skilled in the art that the present invention may be varied in a number of ways without departing from the scope of the invention. All such modifications as would be obvious to one skilled in the art are intended to be included within the scope of this claims.
Claims (7)
1. The surgical liquid dressing is characterized by comprising the following raw materials in percentage by weight: 15.0 to 35.0 percent of rehabilitation liquid, 3.5 to 5.5 percent of antioxidant, 1.5 to 5.0 percent of polyvinylpyrrolidone, 1.0 to 2 percent of sodium alginate, 3.0 to 4.5 percent of glycerol, 0.8 to 1.4 percent of plasticizer, 3.0 to 8.0 percent of humectant and the balance of purified water.
2. The surgical liquid dressing of claim 1, wherein: also comprises 0.008-0.01% of benzalkonium bromide.
3. The surgical liquid dressing of claim 2, wherein: also comprises 0.5 to 1.2 percent of acrylic ester.
4. A surgical liquid dressing according to claim 3, wherein: the antioxidant is vitamin C or vitamin E.
5. A surgical liquid dressing according to claim 3, wherein: the plasticizer is propylene glycol.
6. A surgical liquid dressing according to claim 3, wherein: the humectant is polyethylene glycol.
7. A process for the production of a surgical liquid dressing, comprising the surgical liquid dressing according to any one of claims 1 to 6, the process comprising the steps of:
a. uniformly mixing polyvinylpyrrolidone, sodium alginate, plasticizer, glycerin, humectant, acrylic ester and purified water, stirring, standing for 4-8 h at normal temperature to obtain solution A;
b. adding the antioxidant into the solution A, and stirring and dissolving to obtain a solution B;
c. adding the benzalkonium bromide into the solution B, and uniformly mixing to obtain a solution C;
d. and adding the rehabilitation solution into the solution C, and uniformly mixing to obtain the surgical liquid dressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310204044.5A CN116407673A (en) | 2023-03-06 | 2023-03-06 | Surgical liquid dressing and production process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310204044.5A CN116407673A (en) | 2023-03-06 | 2023-03-06 | Surgical liquid dressing and production process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116407673A true CN116407673A (en) | 2023-07-11 |
Family
ID=87052333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310204044.5A Pending CN116407673A (en) | 2023-03-06 | 2023-03-06 | Surgical liquid dressing and production process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116407673A (en) |
-
2023
- 2023-03-06 CN CN202310204044.5A patent/CN116407673A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2059206B1 (en) | Dry wound dressing and drug delivery system | |
| CN107617121B (en) | Biological induction active dressing for skin wound surface and preparation method and application thereof | |
| CA2409076A1 (en) | Composition and method for growing, protecting, and healing tissues and cells | |
| CN103495199A (en) | Hydrogel wound dressing for treating laser cauma and burns and scalds as well as preparation method thereof | |
| CN105012993A (en) | Medical and antibacterial cationic biogel dressing and preparation method thereof | |
| EP2292257A2 (en) | Compositions and methods for dermatological wound healing | |
| CN108187132A (en) | A kind of povidone iodine hydrogel antiseptic dressing and preparation method thereof | |
| US20080020025A1 (en) | Composition for wound care and method of using same | |
| CN110859989B (en) | Liquid band-aid and preparation method thereof | |
| EP3040087B1 (en) | Wound dressings | |
| CN111068103B (en) | Long-acting antibacterial gel dressing for operation wound and preparation method thereof | |
| IE911403A1 (en) | Compositions and method for topical treatment of damaged or¹diseased tissue | |
| CN111166932B (en) | Liquid wound spray dressing and preparation method thereof | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| CN116407673A (en) | Surgical liquid dressing and production process thereof | |
| KR102096254B1 (en) | Preservative composition comprising unityol and dimethylsulfoxide, use of composition and method of treating wound using same | |
| CN110916900A (en) | Hydrogel medical dressing and preparation method thereof | |
| CN110251716B (en) | Gel dressing for wound care and preparation method thereof | |
| CN109010907B (en) | A kind of functionality Wound-protection liquid body dressing and preparation method thereof | |
| RU2545735C1 (en) | Bioactive hydrogel wound coating | |
| CN107595819B (en) | A kind of Nano diamond modified liquid adhesive bandage and preparation method thereof | |
| WO2007143586A2 (en) | Composition for wound care and method of using same | |
| Foutsizoglou | A practical guide to the most commonly used dressings in wound care | |
| CN117138029B (en) | Composition containing epidermal cytokines and application of composition in bedsore repair | |
| KR101242579B1 (en) | Preparing method of Gel paste for treatment an ulcer including a honey by radiation and Gel paste for treatment an ulcer thereby |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |